Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796551 | 0.86 | F2RL1 (0.42) | ALDH1A1SMN1; SMN2AAK1CTSLCTSS | |
| SCHEMBL8290917 | 0.80 | CTSS (0.62) | CTSLCTSSCTSK | |
| SCHEMBL4798028 | 0.79 | CTSL (0.38) | SMN1; SMN2AAK1CTSLCTSSCTSK | |
| SCHEMBL3840211 | 0.78 | CTSS (0.50) | KLK7CTSLCTSSCTSK | |
| SCHEMBL4799148 | 0.77 | CTSS (0.44) | AAK1CTSLCTSSCTSK | |
| SCHEMBL4798550 | 0.76 | AAK1 (0.42) | AAK1CTSLCTSSCTSK | |
| SCHEMBL4800048 | 0.76 | CTSD (0.42) | ALDH1A1AAK1CTSLCTSSCTSK | |
| SCHEMBL4797862 | 0.76 | CTSS (0.48) | AAK1CTSLCTSSCTSK | |
| SCHEMBL4798054 | 0.75 | CTSS (0.51) | KLK7CTSLCTSSCTSK | |
| SCHEMBL4798738 | 0.74 | CTSD (0.46) | ALDH1A1SMN1; SMN2CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | claimed |
| EP-1658267-A4 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-08-01 | — | — | EP | claimed |
| JP-2007502836-A | — | — | 2007-02-15 | — | — | JP | claimed |
| EP-1658267-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | claimed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | claimed |
| WO-2005034848-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-04-21 | — | — | WO | claimed |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | disclosed |
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-7501408-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| EP-1658267-A4 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-08-01 | — | — | EP | disclosed |
| EP-1658267-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | disclosed |
| WO-2005034848-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | ALDH1A1 3512/4885KLK7 398/4885SMN1; SMN2 2505/4885 |
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | ALDH1A1 3512/4885KLK7 398/4885SMN1; SMN2 2505/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | ALDH1A1 3512/4885KLK7 398/4885SMN1; SMN2 2505/4885 |
| US-20050113356-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | ALDH1A1 3512/4885KLK7 398/4885SMN1; SMN2 2505/4885 |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSE, CTSV | ALDH1A1 2502/4885KLK7 2019/4885SMN1; SMN2 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.